Targeted therapy in relapsed classical Hodgkin lymphoma

Shira Dinner, Ranjana Advani*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Although frontline treatment of advanced Hodgkin lymphoma (HL) produces high cure rates, disease either will not respond to or will relapse after initial therapy in approximately a quarter of patients. Many patients with disease relapse can be successfully salvaged with second-line chemotherapy followed by autologous stem cell transplantation (ASCT). Patients whose disease relapses after ASCT are rarely cured. A unique pathophysiologic feature of HL is that the malignant Reed-Sternberg (HRS) cell is rare and resides within a microenvironment of inflammatory and immunerelated cells. The recent FDA approval of the anti-CD30 antibody- drug conjugate brentuximab vedotin (BV) for patients with either primary refractory HL or those whose disease relapses after ASCT represents a major advance in therapy. This article focuses on BV and other novel agents that target the HRS cell surface, intracellular signaling pathways, and tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)968-976
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2013

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Targeted therapy in relapsed classical Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this